Literature DB >> 7634745

Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects.

J S Jensen1, K Borch-Johnsen, G Jensen, B Feldt-Rasmussen.   

Abstract

1. In epidemiological studies microalbuminuria, i.e. slightly elevated urinary albumin excretion rate, predicts increased atherosclerotic vascular morbidity and mortality. This study aimed to test the hypothesis that microalbuminuria in clinically healthy subjects is associated with a systemic transvascular albumin leakiness. In animal experiments the outflux of albumin and lipids to the arterial wall are highly correlated, and both are elevated in atherosclerosis. 2. All participants were recruited at random from a population-based epidemiological study, where the upper decile of urinary albumin excretion rate was 6.6 micrograms/min. Twenty-seven patients with persistent microalbuminuria (urinary albumin excretion rate 6.6-150 micrograms/min), and 56 age- and sex-matched control subjects with persistent normoalbuminuria (UAER < or = 6.6 micrograms/min) were studied. 3. The systemic transvascular albumin leakage was measured as the fractional disappearance rate of 125I-labelled albumin from the total plasma compartment in 1 h after intravenous injection. 4. The fractional disappearance rate of albumin from the plasma compartment was higher in the microalbuminuric than in the normoalbuminuric group [5.8 (95% confidence interval 5.3-6.2; n = 27) versus 5.0 (4.6-5.5; n = 56)%/h, P < 0.05]. The positive correlation between urinary albumin excretion rate on continuous scale (logarithmically transformed) and the fractional disappearance rate of albumin from the plasma compartment [slope 0.4 (95% confidence interval 0.1-0.7; n = 83), r = 0.29, P < 0.005] was independent of age, sex, smoking status, blood pressure, body size, plasma volume, plasma albumin concentration and concentrations of blood glucose, serum insulin and serum lipids. 5. In conclusion, microalbuminuria is an independent marker of systemic transvascular albumin leakiness in clinically healthy subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7634745     DOI: 10.1042/cs0880629

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  35 in total

Review 1.  The meaning of microalbuminuria in type 1 diabetes: the need for a new paradigm.

Authors:  S G Adler; C C Nast
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

2.  Associations between microalbuminuria and animal foods, plant foods, and dietary patterns in the Multiethnic Study of Atherosclerosis.

Authors:  Jennifer A Nettleton; Lyn M Steffen; Walter Palmas; Gregory L Burke; David R Jacobs
Journal:  Am J Clin Nutr       Date:  2008-06       Impact factor: 7.045

3.  Microalbuminuria as predictor of outcome. Shows promise but large prospective trials are needed.

Authors:  G Evans; I Greaves
Journal:  BMJ       Date:  1999-01-23

4.  Urinary albumin excretion and transcapillary escape rate of albumin in malignancies.

Authors:  L M Pedersen; L Terslev; P G SŁrensen; K H Stokholm
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

Review 5.  Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.

Authors:  Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

Review 6.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 7.  Recent advances in understanding hypertension development in sub-Saharan Africa.

Authors:  A E Schutte; S Botha; C M T Fourie; L F Gafane-Matemane; R Kruger; L Lammertyn; L Malan; C M C Mels; R Schutte; W Smith; J M van Rooyen; L J Ware; H W Huisman
Journal:  J Hum Hypertens       Date:  2017-03-23       Impact factor: 3.012

8.  Peritoneal protein leakage, systemic inflammation, and peritonitis risk in patients on peritoneal dialysis.

Authors:  Jie Dong; Yuan Chen; Suping Luo; Rong Xu; Ying Xu
Journal:  Perit Dial Int       Date:  2013-01-02       Impact factor: 1.756

9.  Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension.

Authors:  Dan Wang; Svend Strandgaard; Jens Iversen; Christopher S Wilcox
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-08-06       Impact factor: 3.619

Review 10.  Cardiometabolic syndrome: pathophysiology and treatment.

Authors:  Jonathan P Castro; Fadi A El-Atat; Samy I McFarlane; Ashish Aneja; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.